Pharmacyclics
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Pharmacyclics sits in the top decile of US sponsors by registered trial count (#351 of 15,742 sponsors by registered trial count).
Pharmacyclics: 54 sponsored US clinical trials, none currently recruiting.
Pharmacyclics sponsors 54 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 46 completed. 11 of these trials are in Phase 3-4 (later-stage) and 42 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Myeloma, with 3 trials.
Top-decile sponsor footprint
Pharmacyclics ranks in the top decile of sponsors by registered trial count (#351 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
46 of 54 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
54 total, page 1 of 2
Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)
NCT03790332
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)
NCT03112174
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)
NCT02959944
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
NCT02947347
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
NCT02910583
Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
NCT02548962
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
NCT02599324
informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia
NCT02582879
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
NCT02401048
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
NCT02436668
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
NCT02403271
Study of Ibrutinib in Subjects With Acute Myeloid Leukemia
NCT02351037
A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
NCT02264574
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease
NCT02195869
Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia
NCT02165397
Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT02142049
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT02077166
Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT01724346
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
NCT01980628
Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma
NCT01962792
Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma
NCT01980654
Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL
NCT01722487
A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
NCT01744691
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT01578707
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
NCT01478581
Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT01325701
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
NCT01236391
Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)
NCT01292135
Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL
NCT01217749
A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer
NCT01149668
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
NCT01109069
Safety of PCI-32765 in Chronic Lymphocytic Leukemia
NCT01105247
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
NCT01020006
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
NCT00849654
Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma
NCT00724984
Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients
NCT00562224
Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer
NCT00365183
Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)
NCT00373204
Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00290004
Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer
NCT00129844
Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients
NCT00473577
A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)
NCT00102505
Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00100711
Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases
NCT00003563
Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
NCT00134186
Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)
NCT00054795
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
NCT00120939
A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma
NCT00096837
Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors
NCT00080041
A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas
NCT00080054
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 23 |
| Phase 2 | 19 |
| Phase 3 | 11 |
How the Pharmacyclics early-phase archive is shaped
54 indexed studies, none listed as recruiting (0% open); 46 completed (85%).
Phase mix: 11 late (III/IV) vs 42 early (I/II) (early-phase heavy).
Top condition: Multiple Myeloma (3 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Pharmacyclics: archived-pipeline peers nationwide
Peers matched on 54 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Pharmacyclics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 54 archived trials
- AdventHealth Translational Research Institute · 54 trials · 24% recruiting
- Auburn University · 54 trials · 24% recruiting
- Brooke Army Medical Center · 54 trials · 11% recruiting
- Corcept Therapeutics · 54 trials · 11% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Pharmacyclics page
54 registered trials is a research-attention snapshot, not an endorsement of Pharmacyclics or any single study.
- None of Pharmacyclics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Multiple Myeloma is the condition Pharmacyclics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Myeloma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Pharmacyclics pipeline card: 54 registered trials from official public datasets.Report a data error.